Your road to fewer transfusions may start with RYTELO
Discover what makes RYTELO different and how it may help people who have lower-risk MDS with anemia (LR-MDS).
Discover what makes RYTELO different and how it may help people who have lower-risk MDS with anemia (LR-MDS).
RYTELO works in a different way than other medicines you may have tried
RYTELO is the only treatment for LR-MDS that works by targeting telomerase, an enzyme that helps abnormal cells multiply.
A deeper look:
The way RYTELO works was evaluated in nonclinical studies, which are studies conducted inside a laboratory instead of with real patients.
RYTELO makes fewer transfusions possible
How RYTELO was studied in patients
RYTELO was studied in 178 adults with LR-MDS who had anemia and needed frequent blood transfusions. Patients could join the study if treatment with an erythropoiesis-stimulating agent did not work, had stopped working, or was not an option for them.
- 118 patients received RYTELO
- 60 patients received a placebo
(a treatment with no active medication)
The goal of the study was to see if patients treated with RYTELO would need fewer red blood cell transfusions compared with those who received placebo. If needed, patients could still receive supportive care treatments like red blood cell transfusions, platelet transfusions, and growth factors.
For many patients, RYTELO made
ZERO transfusions
possible for 8 weeks or more
Nearly 40% of patients taking RYTELO (47 out of 118) required zero red blood cell transfusions for 8 consecutive weeks or more vs 15% of patients taking placebo (9 out of 60).
Some patients went as long as
24 weeks
without a single red blood cell transfusion
28% of patients taking RYTELO (33 out of 118) required ZERO red blood cell transfusions for 24 consecutive weeks or more vs 3% of patients taking placebo (2 out of 60).
Ask your healthcare provider if RYTELO is the right next step for you
The Patient Brochure can help you discuss the possible results and side effects of RYTELO.
